SCHEMBL3413705

SCHEMBL3413705

COc1ccc(Cc2n[nH]c3cc(C)cc(O[C@]4(O)[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]4O)c23)cc1

nearest known ligand 0.45

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ SLC5A2 P31639 19/20 0.45
▸ SLC5A1 P13866 11/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3413714 1.00 SLC5A2 (0.45) SLC5A2SLC5A1
SCHEMBL3411874 0.92 SLC5A2 (0.50) SLC5A2SLC5A1
SCHEMBL3411865 0.92 SLC5A2 (0.50) SLC5A2SLC5A1
SCHEMBL3409295 0.91 SLC5A2 (0.43) SLC5A2SLC5A1
SCHEMBL3409288 0.91 SLC5A2 (0.43) SLC5A2SLC5A1
SCHEMBL3409481 0.90 SLC5A2 (0.45) SLC5A2SLC5A1
SCHEMBL3409485 0.90 SLC5A2 (0.45) SLC5A2SLC5A1
SCHEMBL3411229 0.89 SLC5A2 (0.45) SLC5A2SLC5A1
SCHEMBL3411226 0.89 SLC5A2 (0.45) SLC5A2SLC5A1
SCHEMBL3407070 0.88 SLC5A2 (0.38) SLC5A2SLC5A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES PATEL MONA 2009-04-16 — — US claimed
US-7084124-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-01 — — US claimed
US-20050032711-A1 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — US claimed
US-7816331-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA NV (BE) 2010-10-19 — — US disclosed
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES PATEL MONA 2010-03-11 — — US disclosed
EP-1680414-A4 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA NV (BE) 2009-05-27 — — EP disclosed
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES PATEL MONA 2009-04-16 — — US disclosed
US-7511021-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2009-03-31 — — US disclosed
US-20060217323-A1 Substituted indazole-O-glucosides Tanabe Pharma Corporation (JP) 2006-09-28 — — US disclosed
US-7084124-B2 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA, N.V. (BE) 2006-08-01 — — US disclosed
EP-1680414-A2 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-19 — — EP disclosed
US-20050032711-A1 Substituted indazole-O-glucosides JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — US disclosed
WO-2005011592-A2 SUBSTITUTED INDAZOLE-O-GLUCOSIDES JANSSEN PHARMACEUTICA N.V. (BE) 2005-02-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032711-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 SLC5A2 10/4885SLC5A1 9/4885
US-20100062971-A1 SUBSTITUTED INDAZOLE-O-GLUCOSIDES GYS2, GPR119, UGGT1 SLC5A2 10/4885SLC5A1 9/4885
US-20090099104-A1 SUBSTITUTED INDAZOLES-O- GLUCOSIDES GYS2, GPR119, PYGL SLC5A2 10/4885SLC5A1 11/4885
US-20060217323-A1 Substituted indazole-O-glucosides GYS2, GPR119, UGGT1 SLC5A2 10/4885SLC5A1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback